Covid-19 News

  • One should probably note that in that country at least 60% of the vaccinations were "chinese" doses (from Sinovac)...

  • Vaccine warriors, spin this!


    WHO reviewing Seychelles COVID-19 data after fully vaccinated people test positive

    Reuters


    The World Health Organization said on Tuesday it was reviewing coronavirus data from Seychelles after the health ministry said more than a third of people who tested positive for COVID-19 in the past week had been fully vaccinated.

    The Seychelles are using a Chinese vaccine that has not been independently tested. Apparently, it does not work. Other countries using it have reported it does not work. I described that here already.

  • You don't believe that cases peaking and on a downward tread are the result of vaccination? 10% of 1.2 billion is still a lot of unvaccinated people. What would be interesting is if they vaccinated a whole city for true realtime data for vaccination.

  • The Seychelles are using a Chinese vaccine that has not been independently tested. Apparently, it does not work. Other countries using it have reported it does not work. I described that here already.

    The WHO begs to differ with you Jed. I missed this one too, not that it's breaking news! May 7th


    WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations


    https://www.who.int/news/item/…im-policy-recommendations


    WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG).


    “The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. “We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.”


    WHO’s Emergency Use Listing (EUL) is a prerequisite for COVAX Facility vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.


    The EUL assesses the quality, safety and efficacy of COVID-19 vaccines, as well as risk management plans and programmatic suitability, such as cold chain requirements. The assessment is performed by the product evaluation group, composed by regulatory experts from around the world and a Technical Advisory Group (TAG), in charge of performing the risk-benefit assessment for an independent recommendation on whether a vaccine can be listed for emergency use and, if so, under which conditions.


    In the case of the Sinopharm vaccine, the WHO assessment included on-site inspections of the production facility.


    The Sinopharm product is an inactivated vaccine called SARS-CoV-2 Vaccine (Vero Cell). Its easy storage requirements make it highly suitable for low-resource settings. It is the also first vaccine that will carry a vaccine vial monitor, a small sticker on the vaccine vials that change color as the vaccine is exposed to heat, letting health workers know whether the vaccine can be safely used.


    WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) has also completed its review of the vaccine. On the basis of all available evidence, WHO recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks. Vaccine efficacy for symptomatic and hospitalized disease was estimated to be 79%, all age groups combined.


    Few older adults (over 60 years) were enrolled in clinical trials, so efficacy could not be estimated in this age group. Nevertheless, WHO is not recommending an upper age limit for the vaccine because preliminary data and supportive immunogenicity data suggest the vaccine is likely to have a protective effect in older persons. There is no theoretical reason to believe that the vaccine has a different safety profile in older and younger populations. WHO therefore recommends that countries using the vaccine in older age groups conduct safety and effectiveness monitoring to make the recommendation more robust.


    WHO emergency use listing


    The emergency use listing (EUL) procedure assesses the suitability of novel health products during public health emergencies. The objective is to make medicines, vaccines and diagnostics available as rapidly as possible to address the emergency, while adhering to stringent criteria of safety, efficacy and quality. The assessment weighs the threat posed by the emergency as well as the benefit that would accrue from the use of the product against any potential risks.


    The EUL pathway involves a rigorous assessment of late phase II and phase III clinical trial data as well as substantial additional data on safety, efficacy, quality and a risk management plan. These data are reviewed by independent experts and WHO teams who consider the current body of evidence on the vaccine under consideration, the plans for monitoring its use, and plans for further studies.


    As part of the EUL process, the company producing the vaccine must commit to continue to generate data to enable full licensure and WHO prequalification of the vaccine. The WHO prequalification process will assess additional clinical data generated from vaccine trials and deployment on a rolling basis to ensure the vaccine meets the necessary standards of quality, safety and efficacy for broader availability.


    WHO also listed the Pfizer/BioNTech vaccine for emergency use on 31 December 2020; two AstraZeneca/Oxford COVID-19 vaccines on 15 February 2021, produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India; and COVID-19 vaccine Ad26.COV2.S developed by Janssen (Johnson & Johnson) on 12 March 2021.

  • More from the WHO May 9th


    The Sinopharm COVID-19 vaccine: What you need to know


    https://www.who.int/news-room/…ine-what-you-need-to-know


    The WHO Strategic Advisory Group of Experts (SAGE) on Immunization has issued Interim recommendations for the use of the inactivated COVID-19 vaccine BIBP developed by Sinopharm/China National Pharmaceutical Group.


    Here is what you need to know.


    This article provides a summary of the interim recommendations; the interim recommendations and the background document are also available online.


    Who should be vaccinated first?

    While COVID-19 vaccine supplies are limited, health workers at high risk of exposure and older people should be prioritized for vaccination.


    The vaccine is not recommended for persons younger than 18 years of age, pending the results of further studies in that age group.


    Countries can refer to the WHO Prioritization Roadmap and the WHO Values Framework as guidance for their prioritization of target groups.


    Should pregnant women be vaccinated?

    The available data on the COVID-19 vaccine BIBP in pregnant women are insufficient to assess either vaccine efficacy or vaccine-associated risks in pregnancy. However, this vaccine is an inactivated vaccine with an adjuvant that is routinely used in many other vaccines with a documented good safety profile, including in pregnant women. The effectiveness of the COVID-19 vaccine BIBP in pregnant women is therefore expected to be comparable to that observed in non-pregnant women of similar age.


    In the interim, WHO recommends the use of the COVID-19 vaccine BIBP in pregnant women when the benefits of vaccination to the pregnant woman outweigh the potential risks. To help pregnant women make this assessment, they should be provided with information about the risks of COVID-19 in pregnancy; the likely benefits of vaccination in the local epidemiological context; and the current limitations of safety data in pregnant women. WHO does not recommend pregnancy testing prior to vaccination. WHO does not recommend delaying pregnancy or considering terminating pregnancy because of vaccination.


    Who else can take the vaccine?

    The vaccine can be offered to people who have had COVID-19 in the past. Within 6 months after an initial natural infection, available data show that symptomatic reinfection is uncommon. Given limited vaccine supply, persons with PCR-confirmed SARS-CoV-2 infection in the preceding 6 months may therefore choose to delay vaccination until near the end of this period. In settings where variants of concerns with evidence of immune escape are circulating earlier immunization after infection may be advisable.


    Vaccine effectiveness is expected to be similar in lactating women as in other adults. WHO recommends the use of the COVID-19 vaccine BIBP in lactating women as in other adults. WHO does not recommend discontinuing breastfeeding after vaccination.


    Persons living with human immunodeficiency virus (HIV) are at higher risk of severe COVID-19 disease. Persons living with HIV were not included in the trial but given this is a non-replicating vaccine, persons living with HIV who are a part of the recommended group for vaccination may be vaccinated. Information and counselling, wherever possible, should be provided to inform individual benefit-risk assessment.


    Who is the vaccine not recommended for?

    Individuals with a history of anaphylaxis to any component of the vaccine should not take it.


    Anyone with a body temperature over 38.5ºC should postpone vaccination until they no longer have a fever.


    What’s the recommended dosage?

    SAGE recommends the use of BIBP vaccine as 2 doses (0.5 ml) given intramuscularly. WHO recommends an interval of 3–4 weeks between the first and second dose. If the second dose is administered less than 3 weeks after the first, the dose does not need to be repeated. If administration of the second dose is delayed beyond 4 weeks, it should be given at the earliest possible opportunity. It is recommended that all vaccinated individuals receive two doses.


    How does this vaccine compare to other vaccines already in use?

    We cannot compare the vaccines head-to-head due to the different approaches taken in designing the respective studies, but overall, all of the vaccines that have achieved WHO Emergency Use Listing are highly effective in preventing severe disease and hospitalization due to COVID-19.


    Is it safe?

    SAGE has thoroughly assessed the data on quality, safety and efficacy of the vaccine and has recommended its use for people aged 18 and above.


    Safety data are limited for persons above 60 years of age (due to the small number of participants in clinical trials). While no differences in safety profile of the vaccine in older adults compared to younger age groups can be anticipated, countries considering using this vaccine in persons older than 60 years should maintain active safety monitoring.


    How efficacious is the vaccine?

    A large multi-country Phase 3 trial has shown that 2 doses, administered at an interval of 21 days, have an efficacy of 79% against symptomatic SARS-CoV-2 infection 14 or more days after the second dose. Vaccine efficacy against hospitalization was 79%.


    The trial was not designed and powered to demonstrate efficacy against severe disease in persons with comorbidities, in pregnancy, or in persons aged 60 years and above. Women were underrepresented in the trial. The median duration of follow-up available at the time of evidence review was 112 days.


    Two other efficacy trials are under way but data are not yet available.


    Does it work against new variants of SARS-CoV-2 virus?

    SAGE currently recommends using this vaccine, according to the WHO Prioritization Roadmap.


    As new data becomes available, WHO will update recommendations accordingly. This vaccine has not yet been evaluated in the context of circulation of widespread variants of concern.


    Does it prevent infection and transmission?

    There is currently no substantive data available related to the impact of COVID-19 vaccine BIBP on transmission of SARS-CoV-2, the virus that causes COVID-19 disease.


    In the meantime, WHO reminds of the need to maintain and strengthen public health measures that work: masking, physical distancing, handwashing, respiratory and cough hygiene, avoiding crowds and ensuring adequate ventilation.

  • Next, they will test molnupiravir’s mechanism of action against the polymerases of some of the other viruses the World Health Organization has identified as having high epidemic potential.

    This is a brick head approach. Just extracting the antiviral part. Ivermectin has at least 5 functions in fighting CoV-19.

    - Its a direct antibody and binds to the SARS-CoV-19 spike protein

    - It block the replication of one virus sup-part

    - It block the assembly of the virus

    - It unblocks the interferon production chain

    - It's immune damping - down regulating the cytokine storm


    And best: It's in use since almost 50 years and no adverse effects are known from teh medicament. There are some cross-reactions with other drugs!

  • President of Seychelles refutes doubts over Sinopharm's vaccine efficacy amid COVID-19 surge


    https://www.globaltimes.cn/page/202105/1223207.shtml


    The president of Seychelles has refuted doubts over the effectiveness of China's COVID-19 vaccine produced by Sinopharm amid the epidemic surge in the country. President Wavel Ramkalawan said the vaccine is effectively helping to protect people from getting sick.


    Chinese experts said that questioning by foreign media over the effectiveness of Sinopharm's vaccine is arbitrary and the surge of COVID-19 cases in Seychelles is fueled by multiple factors, such as mutant strains and the level of protective antibodies in the population.


    Seychelles, an island nation located in the Indian Ocean with a population under 100,000, is so far the most vaccinated country in the world with 69 percent of its population having received at least one shot and 61 percent fully vaccinated, according to research published by Our World in Data.


    The Sinopharm vaccine was administered to people aged 18 to 60 while the Covishield, an AstraZeneca vaccine produced in India were given to people above 60 years old, said president Ramkalawan, in an interview with Seychelles News Agency on Monday.


    A new wave that hit Seychelles has put the country in the spotlight as it has reported 2,486 active COVID-19 cases as of Monday with the total count reaching 8,172.


    The surge in the number of COVID-19 cases has raised doubts over the efficacy of the vaccines after the health ministry reportedly said that more than one third of new active cases are people who are fully vaccinated.


    Though it is unknown how many of the inoculated patients were injected with the Sinopharm shot, questioning voices from some foreign media have been mainly targeting the Chinese vaccine.


    President Ramkalawan refuted such doubts on Monday, saying that among people needing hospitalization in the age group of 18 to 60, 80 percent were not vaccinated, which shows the efficacy of the vaccines.


    "People may be infected but they are not sick. Only a small number are. Isn't this how the vaccine is supposed to help us? So, what is happening is normal," he said, noting that the two vaccines that the country has administered have served the population very well.


    Seychelles has not recorded deaths of people that have been fully vaccinated which also proves the efficacy of the vaccine, he stressed.


    A Beijing-based immunologist who requested to remain anonymous told the Global Times on Tuesday that the evaluation of the effectiveness of the Sinopharm vaccine is arbitrary and the causes for the outbreaks in Seychelles should be analyzed with more detailed information about the patients and taking into consideration factors such as mutant strains and the level of protective antibodies in the local population.


    Although data on genetic sequencing is not yet available for infections in Seychelles in April, the B1351 variant, which was first identified in South Africa, was found in the island nation in February, Daniel Lucey, clinical professor of medicine at Dartmouth Geisel School of Medicine, said in a report published by Time.


    The immunologist also pointed to the relaxation of restrictions as a leading cause of the outbreaks in the country since it opened its borders to tourists from abroad on March 25 with no quarantine restrictions for international arrivals.


    "With vaccination alone is very difficult to stop the spread of COVID-19. So, even with vaccinations, it still needs to be strictly controlled," he said.


    Sylvestre Radegonde, Minister of Foreign Affairs and Tourism, said the growing number of new cases in Seychelles shows that people are letting their guards down with the vaccination program.


    "Seychellois are relaxing and think that all is ok because they are vaccinated now. We are letting our guard down, we are not as careful as before," he said.

  • Israel has 50% of the population vaccinated now and the cases go down to <50/day. So this proves we can stop vaccination after 50% latest. With this we are well below flu level.


    Swiss population has 30% antibodies + 10% vaccines. We know from SARS CoV-1 that the immune response for strong corona virus lasts at least for 20 years. So there is really no need to go further and to endanger kids with experimental drugs. So also without extensive vaccination we soon will reach the upper floor.


    Once more:: RNA vaccines contain 30..50% random junk RNA. Not even the smallest test has ever been made whether this junk does any harm or not. Nor does anybody know what junk they fix you.


    Only fools harm/kill themselves! with RNA vaccines.

  • You don't believe that cases peaking and on a downward tread are the result of vaccination? 10% of 1.2 billion is still a lot of unvaccinated people.

    I wouldn't know what the cause is. Perhaps it is because the elections and the mass religious festival at the Ganges ended. Or, perhaps people are frightened, and they are going back to social distancing and partial lockdowns. That is what is happening in Japan. Only 3% of the population in Japan has been vaccinated, but cases have peaked and begun falling again, probably because of social distancing and so on.


    The total of 1.2 billion is not relevant. Vaccinating 10% of any population (large or small) will begin to reduce cases. Or, at least, it will begin to lower the exponent of an increase. Herd immunity does not abruptly turn on at 70%. It comes about gradually. Look at simulations and you will see that 10% begins to have a measurable effect with COVID-10. How measurable depends on many other factors such as how contagious the disease is.



    President of Seychelles refutes doubts over Sinopharm's vaccine efficacy amid COVID-19 surge

    He is being silly. Anyone can see the stuff ain't working. Or if it is working, it is nowhere near as good as the mRNA, J&J and others.


    It is a little hard to know how well something is working without knowing many other details, such as whether people have relaxed the use of masks, social distancing, going to indoor restaurants and so on. An effective vaccine nearly eliminates any chance of being infected, but only if you are vaccinated and you wait 2 weeks. People who are not vaccinated are no safer than they were before, until herd immunity starts to have effect. If the Chinese vaccine worked well, Seychelles would have significant herd immunity by now, but they don't so it doesn't. This isn't complicated.


    There is no doubt that the percent vaccinated with other vaccines correlates with the number of cases. Not precisely, of course; biology is never precise. But, look at the percents for the Israel, UK, the US, France and Italy (on a descending scale) and the correlation is irrefutable. Plus, we know these vaccines produce the necessary antibodies in nearly every patient, so it is not possible they do not work. That would overthrow medical science for the last 130 years. We know the mechanism (antibodies). We can measure the physical effect that prevents the disease. We can see from the statistics that is working. It is case closed. You seldom see such clear-cut, irrefutable results in public health and epidemiology.

  • I believe I posted a study that the Mr and Mrs at biotech ran in 2018 where they did inject 30 mice with the junk all died 18-30 days after injection. I will dig through my files this afternoon and post.

  • Israel has 50% of the population vaccinated now and the cases go down to <50/day. So this proves we can stop vaccination after 50% latest. With this we are well below flu level.

    63% but who's counting? I sure as hell would not want to be the last person in Israel to get sick or die when that can easily be prevented, at no risk. That would be insane. That's like saying "traffic deaths from DUI are way down, so I'll just get drunk and go 60 mph in a 30 mph zone." As long as the disease infects the human population, you can still get the disease from someone outside of Israel, so why take any risk?


    Once more:: RNA vaccines contain 30..50% random junk RNA

    That is complete and utter bullshit. The RNA is only the segment the expresses the needed surface feature to trigger antibodies. Why would anyone put random RNA it it?!? What would be the point? That makes no sense. Modern biologists know exactly what each gene in a segment does. They would not put extra ones or non-functioning ones it it. Also, they rigorously check the final RNA to be certain it has only the original plasmid sequence, and nothing else. See:


    https://www.nytimes.com/intera…-coronavirus-vaccine.html


    You make up the most astounding bullshit! Or you believe it.

  • What Happened in the Animal Trials for mRNA vaccines?

    April 8, 2021


    https://regenerativemc.com/thu…trials-for-mrna-vaccines/


    Animal studies related to mRNA vaccines were definitely difficult to read and analyze. My intent today is to begin to comprehensively present salient features of these studies one at a time addressing concerns of the vaccine being brought up on the internet.


    An interesting fact to note is no animal study went beyond 56 days presumably because the immediate goal was to prove mRNA vaccines could mount a good immune response with little acute adverse effects. Hence, we have no data even in animal studies as to long term adverse effects of mRNA vaccines. mRNA vaccines are still considered experimental and people receiving these vaccines are part of the experiment. Long term data is currently being collected until 2022. Bottom line is we don’t know the long term adverse effects. What can we learn from the animal studies?


    The first study I reviewed entitled, Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS Virus, published in 2012, began by stating, “The research for vaccine development of coronavirus was initiated in 2002 in response to the 2002 spread of SARS which emerged in China and the “concern for reemergence of a deliberate release of the SARS coronavirus”. *


    This study is sited by some researchers who imply, ‘All animals died from autoimmune lung disease after receiving the vaccine upon being challenged with the virus’ Is this true?


    The paper states,” evaluations of an inactivated whole virus vaccine (similar to customary vaccines) in ferrets, nonhuman primates; and a virus-like-particle in mice induced protection against infection but challenged animals (those administered vaccines) exhibited an immunopathologic-type lung disease.”*


    “The virus-like-particle was an rDNA produced S protein injected in mice on day 0 and 28, some were sacrificed for serum antibody measurements and the rest challenged with the virus on day 56. On day 56 those mice were sacrificed and lungs obtained for virus and pathology”*


    The papers’ conclusion was “These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.”*


    All the vaccines used in this research experiment in 2012 triggered hypersensitivity of Th2 immunity. Th2 cells are a subset of CD4+ T helper cells hence the name Th2. The results from this study showed as Th2 immunity triggered by the vaccines increased, the body’s defense system was pushed out of balance and this reaction started to cause tissue breakdown in the lung. This, of course, is concerning.


    However, the vaccines given in this paper were not the same as the current mRNA vaccines. The challenging virus was, of course, not SARS-CoV-2. The animals did not die of the disease, they were sacrificed. All other statements concerning this paper are opinions. Does this paper have anything to do with the current vaccines?


    Next week we will look at Pfizer and Moderna animal studies. What response do these vaccines mount? Are they dangerous? Is the immunity induced by these vaccines effective?


    Have an awesome day! Dr. D


    https://journals.plos.org/plos…1371/journal.pone.0035421 full article

  • https://regenerativemc.com/pfizer-animal-trial-results/


    PPfizer Animal Trial Results

    April 15, 2021

    Animal models play a critical role in all vaccine trials as a means to ensure vaccines are effective as well as safe. The kind of animal used is also critical. They must show a similar course of the disease as do humans. For example, standard laboratory mice are not susceptible to Covid-19 infection because they do not have the same ACE2 receptor sites as humans.** In order to use mice they have to be bred to express the human ACE2 receptors. This receptor is where Covid spikes attach in the lungs causing the cytokine storm and respiratory distress.


    Two animal models have been developed for Covid 19, mice and macaques (monkeys). Interesting, the Syrian hamster is stated to be the closest match to humans for Covid-19 testing. “The lungs of infected hamsters exhibit the pathological lesions analogous to the COVID-19 patients with pneumonia. Moreover, the nAb response exhibited by the infected hamster demonstrated immunity against the succeeding re-challenge studies. Furthermore, the transfusion of convalescent sera into the naïve hamsters mounted the antibody response and hence hindered the viral replication in the lungs.”**. I included this statement to emphasize the considerations involved in selecting the animals to use in the trials.


    The animal models used by Pfizer and Moderna were mice and macaques (monkeys).* Only Pfizer animal studies are being presented today. “SARS-CoV-2 replicates in the upper and lower respiratory tract and causes pulmonary lesions in both rhesus and cynomolgus macaques. Immune responses against SARS-CoV-2 are also similar in both species and equivalent to those reported in milder infections and convalescent human patients.” * Why the Syrian hamster was not used as an animal model is elusive in Covid-19 animal trial literature.


    The following data is from a paper posted September 8, 2020, and entitled,


    A prefusion SARS-CoV-2 spike RNA vaccine is highly Immunogenic


    and prevents lung infection in non-human primates


    24 mice and 18 macaques were injected in the Pfizer Animal Trial with BNT162b2.


    2-4 year old Male Macaques Trial


    6 male macaques were injected with 30 ug of vaccine, 6 were injected with 100 ug of vaccine, and 6 were injected with saline for controls. They were injected twice, 21 days apart. Seven days after Dose 2 the animals were challenged with Sars-Cov 2 virus. Virus neutralization was noted 14 days after the 30 ug dose of vaccine and 7 days after the 100 ug dose of vaccine. The levels of neutralization were 285 for 30 ug dose and 310 for 100 ug dose persisting to Day 56. This level of neutralization was compared to level of neutralization of human convalescent serum of 94 taken 14 days after a positive PCR test in patients ages 18-83. A Th1 immune response was elicited as well as increased CD4 and CD8 cells.


    Vaccination of monkeys reached neutralization titers 10 to 18 times higher than seen on a human convalescent human serum panel. The vaccine generated strong Th1 type CD4 and CD8 T-cell responses in both mice and monkeys. This is a different immune response than presented in last week’s paper in which the macaques lungs were diseased using a different RNA vaccine. With the Pfizer vaccine, the lungs of the macaques were fully protected when challenged by Covid-19 virus. Virus was detected in nasal swabs of non-immunized macaques day 1, 3, 6 after they were challenged with the vaccine, versus virus being detected only on day 1 in immunized macaques. None of the macaques became ill with the virus. The conclusion was,” In general, virus-challenged animals showed no clinical signs of significant disease. We conclude that the 2-4 year old male rhesus macaques challenge model is primarily a SARs-CoV-2 infection model and not for Covid-19 disease model.”*


    Mice Trial


    Mice were immunized with 0.2, 1, or 5 µg or received a buffer control. IgG antibodies developed rapidly at all dose levels in a dose-dependent manner. SARS CoV-2 neutralization increased steadily after immunization to 296 on Day 28 for the 5 µg dose levels in a dose-dependent manner. A high fraction of CD4 and CD8 T-cells, high levels of Th1 cytokines, and low levels of Th2 cytokines were noted in the lymph nodes. Lung changes were not noted. Little mention was made concerning the controls other than B cells were lower in number than in the immunized mice. The mice were not followed after day 28.


    For me, what was learned is the Pfizer vaccine did promote efficient immunization in mice and macaques and did not cause disease using these two models having been followed for 28 and 56 days.


    One paper summarized its conclusions by stating, “Nevertheless, the assessment of the vaccine dependent immune enhancement cannot be extrapolated from animal models and requires a legitimate survey from stage III human trials or the human challenge studies.” **


    The human trials are being done. We do not know the long term effects of mRNA vaccine. Research will be evaluating those long term side effects by 2022.

    le De?s?g.”*”*”*e? *s?

  • Once more:: RNA vaccines contain 30..50% random junk RNA. Not even the smallest test has ever been made whether this junk does any harm or not. Nor does anybody know what junk they fix you.

    Wyttenbach, we all know that you are smarter than all virologists, pandemic experts, biochemical and epidemiological experts out there, but you should be fair to at least accept or not ignore that there were controlled human studies with large patient cohortes and other pre-approval tests and investigations that ended up with the emergency approval of these experimental vaccines in all that Corona-Covid mess. Even if all done and supported by mafia, criminal killers and big pharma anyway.

    Sure nobody knows (except you) what might be long-term results, and we have to wait and see what will cause more damage in the end to humans: catching the virus and suffer potentially from complex so called long-covid symptons or get (any) of this random junk injected and be at least safe by the statistics from todays point of view and not get seriously sick, need hospitalization or die...

  • Our big pharma advocate zorud spread several misinformation and as usual for mafia member he used dirt cheap ad hominem's because his arguments are the usual fake ones.


    All vaccines require animal tests: None were done.


    1) There was no serious phase III study for Pfizer. It was performed completely against all rules - By Pfizer itself. Pfizer did no followup on the 200 person with early side effects --> kicked out of study. No serious testing by PCR for antibodies etc. has been made.

    So for Pfizer we know only one thing. For people that survive the vaccination there is a significant protection for the old virus but not for BR/RSA/IN version. Clusters (UK,FR) show that you can end up in hospital too after two Pfizer jabs.

    We all wait for the Pfizer half year report of the phase III study (should be out since months...) . May be we will get it after all deals are fixed...


    Contrary to Zoruds (that obviously has no background) claim I and all virologists ,doctors etc. exactly know the side effects as these can be found in the EU database:

    http://www.adrreports.eu/de/search_subst.html#

    The sheer number of side effects for RNA vaccines is outrageous high. The death rate is already 4000x above other vaccines e.g. for flue.


    Just to remind you. CoV-19 + Ivermectin = mild cold.

    No long covid with Ivermectin. Long covid is caused (depriving drugs) by criminal minded big pharma that makes money from suffering people and only wants to optimize personal - tax free - income.


    And it looks like Zorud is helping them....

  • You have your opinion, I have mine. I do not agree with all what happened nor was decided by whom to get these vaccines out, I want to see, read and understand both sides, and peak behind the curtain as good as possible. I fully agree with you that I am not as brilliant as you are, but I can easily deal with your arrogance and don't care much about, since even our mods did confirm that you insult almost everybody here with your way of posting and arguing ;-).

    I hope that in the end Ivermectin, the available vaccines or the ones to come, and maybe other potential non-vaccine treatment will help to end this mess, so we are all brave and nice to each other when this Virus will be gone...